Fujisawa Pharmaceutical Articles

XenoPort recruits David Stamler as CMO from Fujisawa

21 July 2008

UPDATE: Yamanouchi drops Phytopharm's Cogane

7 March 2005

Phytopharm plunges as Yamanouchi looks set to drop Cogane development

7 March 2005

Zepharma's business structure unveiled

11 October 2004

EC OKs Yamanouchi and Fujisawa merger

30 August 2004

Fujisawa exits abciximab alliance with Nippon Centocor

12 July 2004

Hatsuo Aoki named president of JPMA

31 May 2004

Fujisawa net income leaps 44.8%, despite only 3.5% sales growth

10 May 2004

RII to monitor Fujisawa and Yamanouchi

26 April 2004

Daiwa Yakuhin to be acquired by Alfresa

2 February 2004

Fujisawa launches Precol as OTC rhinitis drug

5 January 2004

Aventis' Ketek launched in Japan

22 December 2003

Japanese majors Fujisawa and Yamanouchi "to merge by spring 2005"

24 November 2003

Fujisawa below par in fiscal first half

10 November 2003

Aventis' Ketek cleared in Japan for CARTIs

27 October 2003

Pharma firms low down in Japanese R&D spend ranking

18 August 2003

Fujisawa outlines strategic restructuring in interview with Marketletter

23 June 2003

Japanese drugmakers preparing to launch RA products

9 June 2003

Fujisawa launches Synercid in Japan

19 May 2003

Fujisawa to write off investment losses

28 April 2003

Fujisawa adopts fresh management strategy

14 April 2003

Fujisawa set to post 17% profit increase

17 March 2003

Aventis licenses Ketek to Sankyo, Fujisawa

17 February 2003

Sankyo, Fujisawa in cross-licensing deal

27 January 2003

Fujisawa Pharmaceutical research deal with MerLion Pharma

5 August 2002

Fujisawa's tacrolimus in Phase III for IBD

11 March 2002

Sucampo licenses tacrolimus for ophthalmic uses

25 February 2002

Fujisawa launches Protopic Ointment

11 October 2001

Fujisawa launches "Jobs Challenge" policy

11 September 2001

Fujisawa licenses transplant drugs from Aventis

13 July 2001

Fujisawa Pharma equity investment in Quark Biotechnology.

28 June 2001

Fujisawa to license osteoporosis drug from Adir et Cie

24 May 2001

Fujisawa sets up VC fund with ORIX

25 April 2001

Fujisawa to reorganize its European operations

18 January 2001

Fujisawa gains ISO 14001 for its Fuji plant

15 January 2001

Dainippon's overseas future bright for antiulcerant Gasmotin, say HSBC

23 November 2000

Takeda and Fujisawa link up for drug development deal

22 November 2000

Fujisawa gains ISO 14001 certificate for Takaoka plant

22 November 2000

Fujisawa drops migraine compound

5 October 2000

BASF and Hokuriku view pipeline in Japan, envisage 12% contribution by 2005

7 September 2000

Fujisawa sees delay in Protopic review

27 July 2000

Fujisawa sets up business service unit

22 March 2000

Fujisawa to construct new formulation facilities for Protopic

24 February 2000

Fujisawa launches Protopic

29 November 1999

Fujisawa establishes VC fund

9 September 1999

Fujisawa Foundation allocates research grants

2 August 1999

Fujisawa's Vision 2005 program on track, with emphasis on globalization -

12 May 1999

Fujisawa takes realistic approach to "Vision 2005"

11 May 1999

-Fujisawa appointment

18 March 1999

Fujisawa to market Zeneca's Seroquel in Japan

21 January 1999

Mergers & acquisitions in 1998: a lot of wooing but disappointment at the

7 January 1999

Fujisawa Reports Steady Interim Growth

11 November 1998

First Launch Of Cefoselis In Japan

9 September 1998

Fujisawa Market Prograf In Mexico And Taiwan

3 September 1998

Fujisawa Invests $10 Million In ABS

15 June 1998

Fujisawa Sets Up Ethical Charter

28 May 1998

Net Loss Plunges To $270 Million At Fujisawa

21 May 1998

Appointment At JPMA

2 April 1998

Fujisawa Restructuring In The USA, Revises Forecasts

31 March 1998

Stock Commentary Tokyo

26 March 1998

US Justice Dept Fines Fujisawa $20 Million

5 March 1998

Fujisawa To Expand Prograf Marketing

29 January 1998

Appointments At Fujisawa

22 January 1998

Six-Month Sales Up 12.4% at Synthelabo

29 July 1997

Fujisawa Racketeering Claim Reinstated

19 June 1997

Nonconsolidated Interims From Fujisawa

11 November 1996

Fujisawa To Launch Prograf In Spain

2 September 1996

Fujisawa Buys 18.6% Stake In PharMingen

8 April 1996

Fujisawa appointments

8 January 1996

Forecast Changes By Japan Company Handbook

6 November 1995

Fujisawa appointments

18 September 1995

Fujisawa allocates cash to research

14 August 1995

Fujisawa to build new synthetic research laboratory

24 July 1995

Freeze-Dried Hep A Vaccine In Japan

3 July 1995

New Research LabFor Fujisawa

26 June 1995

Fujisawa Pharmaceutical announces new positions

29 May 1995

Fujisawa Net Down Though Operating Income Soars

29 May 1995

-Hokurika Seiyaku and Fujisawa Pharmaceutical push HSR-237

22 May 1995

Pmp Fermentation Products build new plant in Illinois

8 May 1995

Fujisawa Sets Up Home Medical Division

3 April 1995

First World Launch Of Insulin-Like Growth Factor

13 February 1995

Fujisawa's FK838 Enters Phase II Trials

19 December 1994

Forecasts Revised At Fujisawa

10 October 1994

NIPPON GLAXO PROGRAM TO MOVE ZANTAC TO OTC

1 August 1994

FUJISAWA MERGES TAIWANESE SUSIDIARIES

11 July 1994

EXTRAORDINARY INCOME BOOSTS FUJISAWA IN 1994

30 May 1994

JPMA APPOINTMENT

30 May 1994

FUJISAWA PRODUCT UPDATE

28 February 1994

FIRST LAUNCH OF TEIJIN'S TACALCITOL

13 December 1993

FUJISAWA NET INCOME DOWN 44.9% AT INTERIM

15 November 1993

GRANTS FROM FUJISAWA

16 August 1993

FUJISAWA APPOINTMENTS

28 June 1993

PEDIATRIC CEFZON LAUNCHED IN JAPAN

14 June 1993

FIRST LAUNCH OF FUJISAWA'S PROGRAF

7 June 1993

NET INCOME FALLS 77% IN 1992 AT FUJISAWA

31 May 1993

FUJISAWA DEVELOPMENT

10 May 1993

FUJISAWA REVISES 1993 FORECAST

19 April 1993

TOKYO STOCK COMMENT

12 April 1993

FUJISAWA DROPS LYPHOMED LINE

29 March 1993

PROGRAF HEADS NEW JAPANESE APPROVALS

22 March 1993

Showing 1-100 of 112 articles

Go to beginningPreviousNextGo to end